Watch Total Prescribing Details OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed right after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or soon after 3 or more